{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T10:17:56Z","timestamp":1767867476758,"version":"3.49.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100006751","name":"Web Center for Biomedical Research in Physiopathology of Obesity and Nutrition","doi-asserted-by":"publisher","award":["PI09\/90444"],"award-info":[{"award-number":["PI09\/90444"]}],"id":[{"id":"10.13039\/501100006751","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Regional Development Fund) in Madrid, Spain","award":["PI09\/90444"],"award-info":[{"award-number":["PI09\/90444"]}]},{"DOI":"10.13039\/501100003329","name":"MINECO","doi-asserted-by":"publisher","award":["SAF2014-55725"],"award-info":[{"award-number":["SAF2014-55725"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","diabet-metabolism.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolism"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.diabet.2015.10.004","type":"journal-article","created":{"date-parts":[[2015,11,5]],"date-time":"2015-11-05T00:28:21Z","timestamp":1446683301000},"page":"196-199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effects of ethinylestradiol\u2013cyproterone acetate vs. pioglitazone\u2013flutamide\u2013metformin on plasma FGF21 levels in adolescent girls with androgen excess"],"prefix":"10.1016","volume":"42","author":[{"given":"M.","family":"D\u00edaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Gallego-Escuredo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"de Zegher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Villarroya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2015.10.004_bib0070","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI23606","article-title":"FGF-21 as a novel metabolic regulator","volume":"115","author":"Kharitonenkov","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.diabet.2015.10.004_bib0075","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cmet.2013.08.005","article-title":"The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes","volume":"18","author":"Gaich","year":"2013","journal-title":"Cell Metab"},{"key":"10.1016\/j.diabet.2015.10.004_bib0080","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.2337\/db10-0193","article-title":"Obesity is a fibroblast growth factor 21 (FGF21)-resistant state","volume":"59","author":"Fisher","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2015.10.004_bib0085","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrendo.2014.58","article-title":"Hyperinsulinaemic androgen excess in adolescent girls","volume":"100","author":"Ib\u00e1\u00f1ez","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.diabet.2015.10.004_bib0090","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3109\/09513590.2010.487587","article-title":"Serum fibroblast growth factor 21 levels in polycystic ovary syndrome","volume":"26","author":"Gorar","year":"2010","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.diabet.2015.10.004_bib0095","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3109\/00365513.2014.900821","article-title":"Fibroblast growth factor 21 and its relation to metabolic parameters in women with polycystic ovary syndrome","volume":"74","author":"Sahin","year":"2014","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.diabet.2015.10.004_bib0100","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1530\/EJE-14-0539","article-title":"Circulating FGF21 levels is related to nutritional status and metabolic but not hormonal disturbances in polycystic ovary syndrome","volume":"172","author":"Olszanecka-Glinianowicz","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.diabet.2015.10.004_bib0105","doi-asserted-by":"crossref","first-page":"E902","DOI":"10.1210\/jc.2013-1041","article-title":"Oral contraception vs insulin sensitization for 18 months in nonobese adolescents with androgen excess: posttreatment differences in C-reactive protein, intima-media thickness, visceral adiposity, insulin sensitivity, and menstrual regularity","volume":"98","author":"Ib\u00e1\u00f1ez","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2015.10.004_bib0110","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/ijo.2014.76","article-title":"Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients","volume":"39","author":"Gallego-Escuredo","year":"2015","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.diabet.2015.10.004_bib0115","first-page":"jc20152192","article-title":"Fibroblast growth factor 21 and fetuin-A in obese adolescents with and without type 2 diabetes","author":"Reinehr","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2015.10.004_bib0120","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2337\/dc12-0703","article-title":"Fibroblast growth factor 21 predicts the metabolic syndrome and type 2 diabetes in Caucasians","volume":"36","author":"Bobbert","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2015.10.004_bib0125","doi-asserted-by":"crossref","first-page":"465282","DOI":"10.1155\/2012\/465282","article-title":"Metformin stimulates FGF21 expression in primary hepatocytes","volume":"2012","author":"Nygaard","year":"2012","journal-title":"Exp Diabetes Res"},{"key":"10.1016\/j.diabet.2015.10.004_bib0130","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1248\/bpb.34.1120","article-title":"Thiazolidinediones are potent inducers of Fibroblast Growth Factor 21 expression in the liver","volume":"34","author":"Oishi","year":"2011","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.diabet.2015.10.004_bib0135","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/hep.25539","volume":"55","author":"Lomonaco","year":"2012","journal-title":"Hepatology"}],"container-title":["Diabetes & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363615001263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363615001263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T01:29:30Z","timestamp":1537234170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363615001263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S1262363615001263"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2015.10.004","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of ethinylestradiol\u2013cyproterone acetate vs. pioglitazone\u2013flutamide\u2013metformin on plasma FGF21 levels in adolescent girls with androgen excess","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2015.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}